US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO

Veradermics, Inc. (MANE): Six Months Later: Hair Today, Higher Tomorrow, 2026's Breakout Story

Veradermics, Inc. (MANE):Aesthetic & Dermatology Biotech Sets Terms Seeking up to $

Veradermics, Inc. (MANE): Peeking at the IPO Prospectus of an Aesthetic & Dermatology Biotech

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Phase 2 biotech VeraDermics (MANE) targets pattern hair loss, offering 13.35 million shares at $14–$16 for a $467–$534 million valuation.</li>
<li>Wellington Management anchors up to $30 million, providing validation, as channel checks suggest oversubscription from testing-the-waters meetings.</li>
<li>Despite demand, competitive dermatology dynamics, single-asset risk, and a selective IPO market warrant a cautious investment stance.</li>
</ul>


Phase 2 biotech VeraDermics (MANE) targets pattern hair loss, offering 13.35 million shares at $14–$16 for a $467–$534 million valuation.
Wellington Management anchors up to $30 million, providing validation, as channel checks suggest oversubscription from testing-the-waters meetings.
Despite demand, competitive dermatology dynamics, single-asset risk, and a selective IPO market warrant a cautious investment stance.


Veradermics, Inc. (MANE): Wellington Anchors Dermatology Biotech but Caution Needed Around Subsector